올리고뉴클레오티드 합성 시장 보고서 : 제품별, 용도별, 최종 용도별, 지역별(2026-2034년)

The global oligonucleotide synthesis market size reached USD 3.7 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 8.7 Billion by 2034, exhibiting a growth rate (CAGR) of 9.72% during 2026-2034. The growing prevalence of genetic diseases among the masses, the development of novel therapeutic strategies, and the widespread adoption of therapies using small interfering RNAs (siRNAs), and antisense oligonucleotides are some of the major factors propelling the market.

Oligonucleotide synthesis refers to the process of constructing short DNA or RNA molecules, called oligonucleotides, in a predetermined sequence. These can range from just a few bases to around 200 nucleotides in length. The process is accomplished chemically in a controlled laboratory environment, typically using solid phase phosphoramidite chemistry. In this method, nucleotides are sequentially added to a growing chain, each addition involving a series of chemical reactions. This technology enables scientists to generate custom-made oligonucleotides for various applications including gene synthesis, polymerase chain reaction (PCR), gene editing tools, such as CRISPR-Cas9, and molecular diagnostic tests. Advances in oligonucleotide synthesis have dramatically accelerated research in genomics and molecular biology, underpinning many breakthroughs in medical and biological research.

The rising prevalence of genetic diseases among the masses majorly drives the global market. This necessitates the development of novel therapeutic strategies, where oligonucleotide-based therapies play a significant role. For instance, therapies using small interfering RNAs (siRNAs) and antisense oligonucleotides are being investigated and utilized in the treatment of genetic disorders, such as Duchenne muscular dystrophy and spinal muscular atrophy. As such, the growing prevalence of genetic diseases drives the demand on the global level. Along with this, the growth of bioinformatics and data science has a direct impact on the oligonucleotide synthesis industry. The escalating capacity to analyze large genomic datasets is also positively influencing the market. Therefore, the rising computational capability is driving an increased demand for the synthesis of novel oligonucleotides. Furthermore, oligonucleotides particularly antisense oligonucleotides, have been shown to be effective tools in epigenetic research and therapy, helping to modulate gene expression, which is creating a positive market outlook.

OLIGONUCLEOTIDE SYNTHESIS MARKET TRENDS/DRIVERS:

Rising Demand in the Healthcare and Pharmaceutical Industries

The global demand for personalized medicine and therapeutics is rapidly increasing, leading to an unprecedented expansion in the oligonucleotide synthesis market. These synthesized sequences are integral components in developing targeted therapies for various genetic disorders and diseases, including cancer. Along with this, the advancement of therapeutic oligonucleotides, such as antisense oligonucleotides, aptamers, siRNAs, and immunostimulatory oligonucleotides, is revolutionizing disease treatment by specifically inhibiting or altering gene expression. Furthermore, the synthesis of custom oligonucleotides is fundamental to the production of vaccines, including mRNA-based COVID-19 vaccines, which have proven effective and are now widely used. As pharmaceutical companies and researchers continue to discover novel applications for oligonucleotides in the treatment and prevention of diseases, the demand for oligonucleotide synthesis is poised to rise.

Technological Advancements and Innovation

The steady development and refinement of oligonucleotide synthesis technologies are driving market growth. In addition, innovations in the synthesis process, including high-throughput and automated synthesis systems, have increased the efficiency, accuracy, and scalability of oligonucleotide production. Moreover, developments in bioinformatics and synthetic biology , including DNA sequencing and gene editing (e.g., CRISPR-Cas9), heavily rely on the ability to synthesize oligonucleotides accurately. These advancements allow for the creation of custom sequences with greater complexity and diversity and facilitate rapid prototype testing in synthetic biology, thereby fostering more efficient research and development. These continuous technological advancements and developments are also contributing to the market.

Growing Collaborations and Partnerships

Collaborations and partnerships between pharmaceutical companies, biotechnology firms, and research institutions have become essential drivers in advancing the development and commercialization of oligonucleotide therapies for genetic diseases. These collaborations bring together diverse expertise, resources, and funding, creating a synergistic environment that accelerates the translation of scientific discoveries into practical and effective treatments. Pharmaceutical companies, with their experience in drug development, clinical trials, and regulatory processes, contribute vital expertise to the collaboration. They have the infrastructure, knowledge, and resources necessary to navigate the complex landscape of drug development and ensure that oligonucleotide therapies meet regulatory standards for safety and efficacy. Their involvement helps streamline the path to commercialization by leveraging existing networks, manufacturing capabilities, and distribution channels.

OLIGONUCLEOTIDE SYNTHESIS INDUSTRY SEGMENTATION:

Breakup by Product:

• Synthesized Oligonucleotide Products
• Reagents
• Equipment
• Services

Synthesized oligonucleotide products dominate the market

The market for synthesized oligonucleotide products in the oligonucleotide synthesis industry is being driven by the ever-increasing demand from pharmaceutical and biotechnological companies for drug discovery and development, especially for personalized medicine and targeted therapeutics. Along with this, the rise in genomics and molecular research, fueled by significant advancements in technologies such as Next Generation Sequencing (NGS) and CRISPR gene-editing, is enhancing the requirement for synthesized oligonucleotides. Additionally, the growth in diagnostic applications of oligonucleotides, such as in PCR and microarray assays for genetic and infectious diseases, is propelling the market forward. The expanding field of epigenetics also represents a key driver, with oligonucleotides playing a crucial role in gene expression studies. Moreover, the increasing prevalence of genetic disorders and the resultant demand for novel therapeutic strategies involving oligonucleotides further accelerates the market growth for synthesized oligonucleotide products.

Breakup by Application:

• PCR Primers
• PCR Assays and Panels
• Sequencing
• DNA Microarrays
• Fluorescence In-Situ Hybridization (FISH)
• Antisense Oligonucleotides
• Others

PCR primers dominate the market

The demand for PCR primers in the oligonucleotide synthesis industry is driven by the ongoing global health crisis necessitating extensive viral testing, in which PCR is a primary method. Furthermore, the increasing application of PCR in medical diagnostics, forensics, and research to detect genetic mutations and infectious diseases fuels the demand for primers. In the field of genomics and molecular biology, PCR is considered a crucial tool for DNA sequencing, cloning, and genetic manipulation, and this broad utilization further drives the need for PCR primer synthesis. Apart from this, technological advancements in PCR techniques, such as real-time PCR and digital PCR, are also playing a role in boosting demand. Moreoevr, the growing funding for research in healthcare and life sciences has resulted in expanded use of PCR, thus driving the demand for PCR primers in the overall industry.

Breakup by End Use:

• Pharmaceutical and Biotechnology Companies
• Hospital and Diagnostic Laboratories
• Academic Research Institutes

Academic research institutes dominate the market

The demand for oligonucleotide synthesis in academic research institutes is driven by a rise in genomics and molecular biology research, particularly studies related to gene expression, genetic disorders, and the development of novel therapeutic strategies. Additionally, advancements in technologies such as Next-Generation Sequencing (NGS) and CRISPR gene-editing, which rely on synthesized oligonucleotides, are stimulating demand. In addition, the rising trend of interdisciplinary studies involving bioinformatics and data science, which necessitate the use of oligonucleotides for data validation, further drives the need. Governmental and institutional funding for genomics and biotechnology research is another major driver, enabling academic institutes to invest in oligonucleotide synthesis for various projects. Academic research institutes, with their focus on fundamental research and discovery, often possess cutting-edge knowledge and innovative ideas. By partnering with industry, they can translate their scientific findings into practical applications and commercial products.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America exhibits a clear dominance, accounting for the largest oligonucleotide synthesis market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.

The North American market for oligonucleotide synthesis is propelled by a robust pharmaceutical and biotech industry, with a strong focus on drug discovery and development. The region's emphasis on personalized medicine and targeted therapies further propels this need. Additionally, North America's sophisticated healthcare system with advanced diagnostic capabilities increases the demand for oligonucleotides in diagnostic assays. The region also hosts numerous top-tier academic and research institutes conducting extensive genomics and molecular biology research, which necessitates oligonucleotide synthesis. Moreover, strong governmental and private sector investment in healthcare and life sciences research, particularly in genomics and personalized medicine, fuels the growth of industry in North America. Moreover, the advancements in delivery systems and formulations for oligonucleotide-based therapeutics in North America demonstrate the region's commitment to pushing the boundaries of innovation in this field. These developments not only contribute to the growth of the market but also have the potential to revolutionize the treatment of various diseases, including genetic disorders, cancers, and rare diseases.

COMPETITIVE LANDSCAPE:

The global oligonucleotide synthesis market is experiencing significant growth due to the escalating investments in the development of new production facilities, upgrading existing ones, and implementing more efficient production processes. Therefore, Companies are heavily investing in research and development to innovate their offerings, including developing new synthesis techniques, improving the scale and accuracy of synthesis, and creating new types of oligonucleotide products to support various applications in diagnostics, therapeutics, and research. Along with this, companies are entering into strategic collaborations, partnerships, and acquisitions to co-develop oligonucleotide-based drugs, share technology and expertise, or expand into new markets. In addition, the introduction of therapeutics, such as antisense oligonucleotides, siRNAs, and miRNAs, offer new avenues for treating a wide range of diseases, including genetic disorders and cancers is positively influencing the market. Furthermore, key players are offering services for the custom synthesis of oligonucleotides. This allows researchers and developers to order specific oligonucleotide sequences tailored to their needs, which is particularly important in fields like genomics, molecular biology, and personalized medicine.

The report has provided a comprehensive analysis of the competitive landscape in the global oligonucleotide synthesis market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

• Agilent Technologies Inc.
• Biolegio B.V.
• Bio-Synthesis Inc
• Eurofins Genomics
• GenScript
• Horizon Discovery Ltd
• Integrated DNA Technologies Inc (Danaher Corporation)
• Kaneka Eurogentec S.A. (Kaneka Corporation)
• LGC Limited
• Nitto Denko Avecia Inc (Nitto Denko Corporation)
• Thermo Fisher Scientific Inc.

Key Questions Answered in This Report

• 1.What was the size of the global oligonucleotide synthesis market in 2025?
• 2.What is the expected growth rate of the global oligonucleotide synthesis market during 2026-2034?
• 3.What are the key factors driving the global oligonucleotide synthesis market?
• 4.What has been the impact of COVID-19 on the global oligonucleotide synthesis market?
• 5.What is the breakup of the global oligonucleotide synthesis market based on the product?
• 6.What is the breakup of the global oligonucleotide synthesis market based on the application?
• 7.What is the breakup of the global oligonucleotide synthesis market based on end use?
• 8.What are the key regions in the global oligonucleotide synthesis market?
• 9.Who are the key players/companies in the global oligonucleotide synthesis market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Oligonucleotide Synthesis Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Synthesized Oligonucleotide Products
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Reagents
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Equipment
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Services
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Application

• 7.1 PCR Primers
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 PCR Assays and Panels
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Sequencing
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 DNA Microarrays
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Fluorescence In-Situ Hybridization (FISH)
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Antisense Oligonucleotides
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast
• 7.7 Others
  • 7.7.1 Market Trends
  • 7.7.2 Market Forecast

8 Market Breakup by End Use

• 8.1 Pharmaceutical and Biotechnology Companies
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Hospital and Diagnostic Laboratories
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Academic Research Institutes
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Agilent Technologies Inc.
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 Biolegio B.V.
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
  • 14.3.3 Bio-Synthesis Inc
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
  • 14.3.4 Eurofins Genomics
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
  • 14.3.5 GenScript
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
  • 14.3.6 Horizon Discovery Ltd
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
  • 14.3.7 Integrated DNA Technologies Inc (Danaher Corporation)
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
  • 14.3.8 Kaneka Eurogentec S.A. (Kaneka Corporation)
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
  • 14.3.9 LGC Limited
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
  • 14.3.10 Nitto Denko Avecia Inc (Nitto Denko Corporation)
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
  • 14.3.11 Thermo Fisher Scientific Inc.
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
    • 14.3.11.3 Financials
    • 14.3.11.4 SWOT Analysis